Share：
Share this content in WeChat
X
[Chinese][PDF]763104
• Review •
Application of magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy in breast cancer
YIN Yuan-yuan  WANG Hong  MU Xue-tao 

DOI:10.3969/j.issn.1674-8034.2013.06.017.


[Abstract] With the increasingly morbidity and mortality associated with breast cancer, neoadjuvant chemotherapy has become an essential part of combination therapy for patients with breast cancer. MRI could show the tumor size and margin clearly. Furthermore, functional MRI technology, including DCE-MRI, DWI, PWI and MRS, could early predict the response to neoadjuvant chemotherapy before the tumor morphology changes. It provided an important reference for optimal chemotherapy program. This review focuses on the role of MRI in predicting the efficacy of neoadjuvant chemotherapy for breast cancer.
[Keywords] Breast cancer；Magnetic resonance imaging

YIN Yuan-yuan Graduate School of Liaoning Medical University, Jinzhou 121001, China; Department of Magnetic Resonance Imaging, Armed Police General Hospital, Beijing 100039, China

WANG Hong * Department of Magnetic Resonance Imaging, Armed Police General Hospital, Beijing 100039, China

MU Xue-tao Department of Magnetic Resonance Imaging, Armed Police General Hospital, Beijing 100039, China

*Correspondence to: Wang Hong, E-mail: wanghongmri@sina.com

Conflicts of interest   None.

Received  2013-08-16
Accepted  2013-10-10
DOI: 10.3969/j.issn.1674-8034.2013.06.017
DOI:10.3969/j.issn.1674-8034.2013.06.017.

[1]
Misra S, Solomon NL, Moffat FL, et al. Screening criteria for breast cancer. Adv Surg, 2010, 44: 87-100.
[2]
Keune JD, Jeffe DB, Schootman M, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg, 2010, 199(4): 477-484.
[3]
Mieog JS, van de Velde CJ. Neoadjuvant chemotherapy for early breast cancer. Expert Opin Pharmacother, 2009, 10(9): 1423-1434.
[4]
颜宝云．动态增强磁共振及扩散加权成像对乳腺癌新辅助化疗疗效评价的应用研究．山西医科大学硕士学位论文, 2011.
[5]
Charfare H, Limongelli S, Purushotham AD, et al. Neoadjuvant chemotherapy in breast cancer. Br J Surg, 2005, 92(7): 14-23.
[6]
Caudle AS, Hunt KK. The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr Opin Obstet Gynecol, 2011, 23(1): 31-36.
[7]
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 2008, 26(5): 778-785.
[8]
Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol, 2002, 179(5): 1193-1199.
[9]
Shah SK, Shah SK, Greatrex KV. Current role of magnetic resonance imaging in breast imaging:a primer for the primary care physician. J Am Board Fam Pract, 2005, 18(6): 478-490.
[10]
Izzo I, Stasolla A, Basso L, et al. Characterization of tumor allusions of breast preliminary experience with multislice spiral CT. Exp Clin Cancer Res, 2005, 24(2): 209-214.
[11]
Bombardieri E, Aktolun C, Baum RP, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging, 2003, 30(12): 115-124.
[12]
孙冰，宋三泰，吴世凯，等．乳腺癌新辅助化疗疗效评价方法的比较．中华肿瘤杂志, 2009, 31(10): 783-785.
[13]
张仁知．磁共振成像评价乳腺癌新辅助化疗疗效的应用研究及进展．北京协和医学院中国医学科学院博士研究生学位论文, 2011.
[14]
Yeh E, Slanetz P, Kopans DB, et al. Prospective comparision of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol, 2005, 184(3): 868-877.
[15]
Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer, 2008, 112(1): 17-26.
[16]
Balu-Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat, 2002, 72: 145-152.
[17]
Werner-Wasik M, Xiao Y, Pequignot E, et al. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys, 2001, 51(1): 56-61.
[18]
Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop, 2000, (376): 200-208.
[19]
Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessment to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2005, 92(3): 231-238.
[20]
汪晓红，彭卫军，信超，等．动态增强MRI监测乳腺癌新辅助化疗疗效的应用价值．中华肿瘤学杂志, 2010, 32(7): 539-543.
[21]
李敏，金真，李功杰，等．乳腺动态增强MRI参数与肿瘤血管的相关性及其鉴别诊断价值．磁共振成像, 2010, 1(1): 36-42.
[22]
Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther, 2003, 2(4): 419-426.
[23]
George ML, Dzik-Jurasz AS, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg, 2001, 88(12):1628-1636.
[24]
Englmeier KH, Hellwig G, Griebel J, et al. Dynamic MR-mammography in virtual reality. Stud Health Technol Inform, 2003, 94: 72-78.
[25]
Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology, 2004, 232(3): 685-692.
[26]
顾雅佳，冯晓源．乳腺癌边缘确定及治疗疗效评价的磁共振弥散成像研究．复旦大学博士学位论文. 2006.
[27]
Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology,1988,168(2): 497-505.
[28]
Moffat BA, Hall DE, Stojanovska J, et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magn Reson Mater Phys Biol Med, 2004,17(3-6): 249-259.
[29]
Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging:pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology, 2010, 257(1): 56-63.
[30]
顾雅佳，冯晓源，邱龙华，等. DWI对局部进展期乳腺癌新辅助化疗疗效评价的初步进展．放射学实践, 2007, 22(12): 1249-1255.
[31]
吴家豪，何劲松，倪勇，等．乳腺癌新辅助化疗疗效评价方法进展.癌症, 2010, 29(2): 240-244.
[32]
Martin D, Gibbs P, Lowry M, et al. Diffusion changes preeede size reduetion in neoadjuvant treatment of breast cancer. Magn Reson Imagjng, 2006, 24(7): 843-847.
[33]
Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging, 2006, 24(7): 843-847.
[34]
张仁知，周纯武．氢质子磁共振波谱成像监测乳腺癌新辅助化疗疗效研究进展．磁共振成像, 2012, 3(2): 153-156.
[35]
Meisamy S, Bolan PJ, Baker EH. et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H-MR spectroscopy a pilot study at 4 T. Radiology, 2004, 233(2): 424-431.
[36]
汪晓红，彭卫军，沈坤炜，等. fMRI监测乳腺癌新辅助化疗疗效的应用.放射学实践, 2007, 22(11): 1135-1138.
[37]
Baek HM, Chen JH, Nie K, et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H-MR spectroscopy. Radiology, 2009, 251(3): 653-662.
[38]
汪晓红，彭卫军，顾雅佳，等. T2*磁共振灌注成像监测乳腺癌新辅助化疗疗效的应用研究．杭州：中华医学会放射学分会, 2009: 262.
[39]
胡文娟，张蓓，潘玉林，等．磁共振灌注成像对局部进展期乳腺癌新辅助化疗疗效的评价．放射学实践, 2011, 26(1): 25-29.

PREV Clinical application and advancement of small-bowel MRI
NEXT Differentiation between recurrent gliomas and radiation-induced brain injuries using DCE-MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn